CMB305
Phase 2- Indications
- Soft tissue sarcoma
Company intelligence / Profile preview
Immune Design developed two synergistic immunotherapy platforms with clinical programs ranging from preclinical to randomized Phase 2. Their lead candidate G100 showed clinical benefit as an intratumoral TLR4 agonist in multiple tumor types. The company also had ongoing pharmaceutical collaborations for infectious disease and allergy indications
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Immune Design.